Share on StockTwits

Investment analysts at Cowen and Company boosted their price target on shares of CymaBay Therapeutics (NASDAQ:CBAY) from $9.00 to $15.00 in a note issued to investors on Friday. The firm currently has an “outperform” rating on the stock. Cowen and Company’s price target would suggest a potential upside of 172.73% from the stock’s previous close.

Shares of CymaBay Therapeutics (NASDAQ:CBAY) opened at 5.50 on Friday. CymaBay Therapeutics has a 52-week low of $5.00 and a 52-week high of $13.776. The stock has a 50-day moving average of $6.0 and a 200-day moving average of $7.38.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.